Lv1
68 积分 2025-08-12 加入
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations
9天前
已完结
The next generation of antibody–drug conjugates
15天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
2个月前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study
3个月前
已完结
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
4个月前
已完结
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
5个月前
已关闭
Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis
5个月前
已完结
Antibody-drug conjugates: new drugs – new toxicities
5个月前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
5个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
